ISA101b

Generic Name
ISA101b
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
-
Background

ISA101b (peltopepimut-S) is a therapeutic vaccine against the HPV-specific E6/E7 oncoproteins.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

Phase 2
Active, not recruiting
Conditions
Cervical Cancer
Interventions
Drug: Cemiplimab
Biological: ISA101b
First Posted Date
2020-11-27
Last Posted Date
2023-10-03
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
113
Registration Number
NCT04646005
Locations
🇺🇸

Arizona Oncology Associates, Tucson, Arizona, United States

🇧🇪

Universitair Ziekenhuis Gent, Gent, East Flanders, Belgium

🇧🇪

CHIREC Delta Hospital / Chirec Cancer Institute, Brussels, Belgium

and more 22 locations

A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Phase 2
Active, not recruiting
Conditions
Squamous Cell Carcinoma of the Oropharynx
Interventions
Drug: ISA101b
First Posted Date
2020-05-21
Last Posted Date
2024-01-16
Lead Sponsor
ISA Pharmaceuticals
Target Recruit Count
65
Registration Number
NCT04398524
Locations
🇧🇪

University Hospital Antwerp, Antwerp, Belgium

🇧🇪

Centre Hospitalier Universitaire de Liege, Liège, Belgium

🇫🇷

Georges Pompidou European Hospital, Paris, France

and more 38 locations

HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

First Posted Date
2020-04-30
Last Posted Date
2024-10-04
Lead Sponsor
Dan Zandberg
Target Recruit Count
18
Registration Number
NCT04369937
Locations
🇺🇸

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy